Orchid BioSciences
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of AstraZeneca subsidiary Cellmark Diagnostics allows Orchid to market SNP scoring and clinical genetic diversity testing services in Europe. The deal will be earnings accretive within 12-to-18 months and will "enable [Orchid] to begin to perform large scale, clinical quality SNP scoring for customers and collaborators in the near future," Orchid notes. U.K.-based Cellmark sells and conducts tests for genetic-based diseases, including cystic fibrosis